Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 10/20 | 0.41 |
| ▸ | KISS1R | Q969F8 | 5/20 | 0.40 |
| ▸ | GNRHR | P30968 | 3/20 | 0.39 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30958914 | 0.99 | KISS1R (0.41) | BACE1KISS1RGNRHRBDKRB2CTSD | |
| SCHEMBL30918331 | 0.92 | KISS1R (0.38) | BACE1KISS1RGNRHRBDKRB2CTNNB1 | |
| SCHEMBL30918341 | 0.82 | CTSB (0.38) | BACE1KISS1RCTNNB1 | |
| SCHEMBL30918311 | 0.82 | PTPN1 (0.42) | — | |
| SCHEMBL30552202 | 0.79 | KISS1R (0.47) | KISS1RGNRHRCTNNB1 | |
| SCHEMBL29631784 | 0.78 | KISS1R (0.46) | KISS1RGNRHR | |
| SCHEMBL30663329 | 0.77 | ACE (0.48) | BACE1KISS1RCTNNB1 | |
| SCHEMBL30958909 | 0.77 | BACE1 (0.39) | BACE1KISS1RCTSD | |
| SCHEMBL30958913 | 0.76 | BACE1 (0.54) | BACE1KISS1RCTSD | |
| SCHEMBL29390652 | 0.74 | MME (0.49) | KISS1RGNRHRBDKRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4622991-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | Janssen Pharmaceutica NV (BE) | 2025-10-01 | — | — | EP | claimed |
| WO-2024110477-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | JANSSEN PHARMACEUTICA NV (BE) | 2024-05-30 | — | — | WO | claimed |
| EP-4622991-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | Janssen Pharmaceutica NV (BE) | 2025-10-01 | — | — | EP | disclosed |
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | VIP, QPCT, PTMS | BACE1 1969/4885KISS1R 1618/4885GNRHR 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.